Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Angiogenic switch in multiple myeloma.

Nicola Giuliani1, Simona Colla, Vittorio Rizzoli

  • 1Chair of Hematology and BMT Center, University of Parma, Parma, Italy. n_giuliani@yahoo.com

Hematology (Amsterdam, Netherlands)
|March 15, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term prognostic impact of chromosome 1 abnormalities in newly diagnosed multiple myeloma patients: a monocentric study.

Annals of hematology·2026
Same author

Understanding the Molecular Mechanisms Underlying Anemia in Myelodysplastic Syndromes: From Erythropoiesis to New Therapeutic Approaches.

Blood cancer discovery·2026
Same author

Author Correction: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.

Nature·2026
Same author

Oncolytic bovine herpesvirus type 1 induces immune microenvironment remodeling and enhances treatment responses in multiple myeloma.

Haematologica·2026
Same author

Aberrant oxidative metabolism selects for <i>TET2</i> -deficient hematopoietic stem and progenitor cells.

bioRxiv : the preprint server for biology·2026
Same author

A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasone.

Haematologica·2026
Same journal

Raloxifene inhibits the proliferation of pediatric acute myeloid leukemia by targeting the ANP32B gene and regulating C-MYC expression.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Characterization of a novel α-thalassemia deletion (Dongxing deletion; --<sup>DX</sup>) by CNV-seq in a Chinese female with Hb H disease: a case report.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Real-world pegcetacoplan treatment of paroxysmal nocturnal hemoglobinuria patients with an unsatisfactory response to prior therapies.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Sirolimus-based treatment regimens for antinuclear antibody (ANA)-positive immune thrombocytopenia: a retrospective single-center cohort study.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Relationship between major depressive disorder and venous thromboembolism: a five-ancestry genetic analysis.

Hematology (Amsterdam, Netherlands)·2026
See all related articles

Angiogenesis, the formation of new blood vessels, is crucial in cancer. In multiple myeloma, increased bone marrow angiogenesis correlates with disease progression and poor prognosis, driven by myeloma cells and their microenvironment.

Area of Science:

  • Oncology
  • Hematology
  • Vascular Biology

Background:

  • Angiogenesis, or new blood vessel formation, is a critical process in cancer development and progression.
  • An imbalance between pro-angiogenic and anti-angiogenic factors is understood to drive the 'angiogenic switch' in tumors.
  • Recent research highlights the role of angiogenesis in hematological malignancies, including multiple myeloma.

Purpose of the Study:

  • To review the key factors contributing to the angiogenic switch in multiple myeloma (MM).
  • To explore the complex pathophysiology of angiogenesis in the context of MM.
  • To summarize current understanding of myeloma-induced angiogenesis.

Main Methods:

  • Literature review focusing on angiogenesis in multiple myeloma.

Related Experiment Videos

  • Analysis of studies investigating angiogenic molecules and their role in MM pathophysiology.
  • Synthesis of data on the correlation between bone marrow angiogenesis, disease progression, and prognosis in MM patients.

    • Main Results:

    • Increased bone marrow angiogenesis is observed in patients with active multiple myeloma.
    • Higher levels of angiogenesis in MM are significantly correlated with disease progression.
    • Myeloma-induced angiogenesis is a complex process involving both myeloma cells and the bone marrow microenvironment.

    Conclusions:

    • Angiogenesis plays a significant role in the progression of multiple myeloma.
    • Understanding the factors driving angiogenesis in MM is crucial for developing targeted therapies.
    • Targeting angiogenesis may offer a promising therapeutic strategy for multiple myeloma patients.